Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
May 12, 2023
MFC's Q3 Earnings Decline by 24.10% to 59 Cents per Share

MFC's Q3 Earnings Decline by 24.10% to 59 Cents per Share

Introduction: On May 05, 2023, Manulife Financial Corporation (MFC) experienced a noteworthy shift in momentum as its Momentum Indicator crossed above the 0 level. This development suggests a potential upward movement in the stock's price. Traders and investors may find this signal enticing, considering historical data and insights from Tickeron's A.I.dvisor. Additionally, the recent earnings report released on May 10 showcased impressive results, surpassing analyst expectations. In this article, we will delve into these two significant factors and their implications for MFC's future prospects.

Positive Momentum Indicator: When a stock's Momentum Indicator moves above the 0 level, as observed with MFC on May 05, it typically signifies a shift towards an upward trend. This technical analysis indicator provides traders with a potential buying opportunity, indicating the possibility of a bullish move. In the case of MFC, Tickeron's A.I.dvisor examined 95 similar instances where the indicator turned positive, and in 62 of those cases, the stock moved higher in the subsequent days. Based on historical data, there is a 65% chance that  MFC will continue its upward trajectory.

Impressive Earnings Beat: MFC's recent earnings report, released on May 10, revealed earnings per share (EPS) of 79 cents, surpassing the estimated value of 58 cents. This impressive earnings beat indicates that the company outperformed analyst expectations, reflecting positive financial performance. It showcases MFC's ability to generate substantial profits and potentially attract investors seeking strong returns. With 313.72K shares outstanding, the current market capitalization of MFC stands at an impressive 36.87 billion dollars.

Market Impact and Future Outlook: The positive momentum observed in MFC, along with the earnings beat, suggests that the stock may continue to experience upward movement in the near term. Traders and investors seeking opportunities could consider buying the stock or purchasing call options to capitalize on this potential uptrend.

Furthermore, MFC's robust earnings performance reflects the company's ability to navigate market conditions effectively and deliver value to its shareholders. The higher-than-expected earnings per share is indicative of a solid business model, efficient operations, and potentially positive growth prospects. These factors, combined with the positive momentum, contribute to an optimistic outlook for MFC.

Conclusion: Manulife Financial Corporation's stock, MFC, has demonstrated a significant shift in momentum, indicating the potential for an upward move. Historical analysis suggests a favorable probability of MFC continuing its upward trajectory based on similar instances in the past. Furthermore, the recent earnings report revealed an impressive earnings beat, demonstrating the company's ability to generate substantial profits.

Traders and investors may find MFC an attractive option for potential gains, considering the positive momentum and strong financial performance.

MFC Trading results, last 6 months

Related Ticker: MFC

Contributor

Dem Sem's AvatarDem Sem|Expert

MFC in +0.74% Uptrend, advancing for three consecutive days on August 04, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MFC advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Aroon Indicator entered an Uptrend today. In of 334 cases where MFC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MFC moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where MFC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MFC as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for MFC turned negative on August 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MFC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MFC broke above its upper Bollinger Band on July 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.177) is normal, around the industry mean (1.440). P/E Ratio (16.569) is within average values for comparable stocks, (20.805). Projected Growth (PEG Ratio) (0.870) is also within normal values, averaging (1.304). Dividend Yield (0.031) settles around the average of (0.045) among similar stocks. P/S Ratio (1.792) is also within normal values, averaging (1.328).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MFC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are MetLife (NYSE:MET), Prudential Financial (NYSE:PRU), Lincoln National Corp (NYSE:LNC), Genworth Financial (NYSE:GNW).

Industry description

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Life/Health Insurance Industry is 19.12B. The market cap for tickers in the group ranges from 228.36K to 154.94B. PIAIF holds the highest valuation in this group at 154.94B. The lowest valued company is GWGHQ at 228.36K.

High and low price notable news

The average weekly price growth across all stocks in the Life/Health Insurance Industry was -4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 4%. MET experienced the highest price growth at 1%, while CIA experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Life/Health Insurance Industry was -14%. For the same stocks of the Industry, the average monthly volume growth was 33% and the average quarterly volume growth was -33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 37
P/E Growth Rating: 72
Price Growth Rating: 51
SMR Rating: 85
Profit Risk Rating: 62
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
MFC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of life and health insurance and reinsurance services

Industry LifeHealthInsurance

Profile
Details
Industry
Life Or Health Insurance
Address
200 Bloor Street East
Phone
+1 416 926-3000
Employees
38000
Web
https://www.manulife.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
MFC's Q3 Earnings Decline by 24.10% to 59 Cents per Share